Stocks
Aerie Pharmaceuticals Financial Statements (AERI) |
||||||||||
| Aerie Pharmaceuticalssmart-lab.ru | % | 2021Q3 | 2021Q4 | 2022Q1 | 2022Q2 | 2022Q3 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 05.11.2021 | 25.02.2022 | 06.05.2022 | 05.08.2022 | 04.11.2022 | 04.11.2022 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 29.3 | 114.7 | 29.8 | 33.3 | 36.1 | 213.9 | |||
| Operating Income, bln rub | -32.4 | 53.5 | -33.6 | -18.1 | -25.1 | -23.2 | ||||
| EBITDA, bln rub | ? | -22.7 | 63.3 | -30.0 | -14.7 | -21.7 | -3.07 | |||
| Net profit, bln rub | ? | -39.7 | 45.5 | -35.9 | -19.4 | -26.8 | -36.6 | |||
| OCF, bln rub | ? | -18.9 | -30.1 | 61.9 | -13.2 | -11.4 | 7.17 | |||
| CAPEX, bln rub | ? | 1.16 | 0.751 | 1.60 | 1.37 | 0.813 | 4.53 | |||
| FCF, bln rub | ? | -20.0 | -30.9 | 60.3 | -14.6 | -12.2 | 2.64 | |||
| Dividend payout, bln rub | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0 | ||||
| OPEX, bln rub | 53.8 | 56.9 | 56.7 | 47.7 | 55.9 | 217.1 | ||||
| Cost of production, bln rub | 7.90 | 6.07 | 6.78 | 3.74 | 6.93 | 23.5 | ||||
| R&D, bln rub | 19.1 | 20.8 | 25.2 | 19.6 | 22.0 | 87.6 | ||||
| Interest expenses, bln rub | 7.36 | 7.52 | 1.63 | 1.19 | 1.65 | 12.0 | ||||
| Assets, bln rub | 351.8 | 431.4 | 395.5 | 385.3 | 375.6 | 375.6 | ||||
| Net Assets, bln rub | ? | -72.9 | -17.3 | -125.7 | -141.1 | -164.0 | -164.0 | |||
| Debt, bln rub | 254.6 | 260.6 | 337.2 | 337.3 | 337.0 | 337.0 | ||||
| Cash, bln rub | 167.6 | 139.8 | 195.2 | 184.4 | 172.5 | 172.5 | ||||
| Net debt, bln rub | 87.0 | 120.8 | 141.9 | 152.9 | 164.5 | 164.5 | ||||
| Ordinary share price, rub | 11.4 | 7.02 | 9.10 | 7.50 | 15.1 | 15.2 | ||||
| Number of ordinary shares, mln | 46.3 | 46.7 | 47.5 | 47.6 | 47.8 | 47.8 | ||||
| Market cap, bln rub | 528 | 328 | 432 | 357 | 724 | 728 | ||||
| EV, bln rub | ? | 615 | 449 | 574 | 510 | 888 | 893 | |||
| Book value, bln rub | -73 | -17 | -126 | -141 | -164 | -164 | ||||
| EPS, rub | ? | -0.86 | 0.98 | -0.76 | -0.41 | -0.56 | -0.76 | |||
| FCF/share, rub | -0.43 | -0.66 | 1.27 | -0.31 | -0.26 | 0.06 | ||||
| BV/share, rub | -1.57 | -0.37 | -2.65 | -2.97 | -3.43 | -3.43 | ||||
| EBITDA margin, % | ? | -77.3% | 55.2% | -100.4% | -44.2% | -60.2% | -1.44% | |||
| Net margin, % | ? | -135.4% | 39.7% | -120.3% | -58.2% | -74.3% | -17.1% | |||
| FCF yield, % | ? | -9.43% | -31.3% | -2.61% | -1.45% | 0.36% | 0.36% | |||
| ROE, % | ? | 228.4% | 431.6% | 54.7% | 35.0% | 22.3% | 22.3% | |||
| ROA, % | ? | -47.3% | -17.3% | -17.4% | -12.8% | -9.73% | -9.73% | |||
| P/E | ? | -3.17 | -4.38 | -6.29 | -7.22 | -19.8 | -19.9 | |||
| P/FCF | -10.6 | -3.20 | -38.3 | -69.1 | 274.4 | 276.2 | ||||
| P/S | ? | 5.07 | 1.69 | 2.15 | 1.72 | 3.38 | 3.40 | |||
| P/BV | ? | -7.25 | -18.9 | -3.44 | -2.53 | -4.41 | -4.44 | |||
| EV/EBITDA | ? | -6.40 | -57.4 | -49.3 | -127.2 | -288.9 | -290.4 | |||
| Debt/EBITDA | -0.90 | -15.5 | -12.2 | -38.2 | -53.5 | -53.5 | ||||
| R&D/CAPEX, % | 1 645% | 2 776% | 1 576% | 1 429% | 2 705% | 1 933% | ||||
| CAPEX/Revenue, % | 3.97% | 0.65% | 5.35% | 4.11% | 2.25% | 2.12% | ||||
| Aerie Pharmaceuticals shareholders | ||||||||||
